Ritlecitinib (Litfulo)

Indications

Treatment of severe alopecia areata in adults and adolescents 12 years of age and older

Sizes Available

Ritlecitinib irreversibly and selectively inhibitsjanus kinase (JAK) 3 and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family by blocking the adenosine triphosphate (ATP) binding site. In cellular settings, ritlecitinib specifically inhibits γ -common cytokines (IL-2, IL-4, IL-7, IL-15 and IL-21) signalling through JAK3-dependent common-γ chain receptors.

More on: Alopecia treatments